Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.906
+0.046 (2.47%)
Sep 5, 2025, 4:00 PM - Market closed
Company Description
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company has a strategic alliance with University of Alabama for the development of ai² future labs program.
The company was incorporated in 2020 and is based in Matawan, New Jersey.
Apimeds Pharmaceuticals US, Inc.
Country | United States |
Founded | 2020 |
IPO Date | May 9, 2025 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 2 |
CEO | Erik Emerson |
Contact Details
Address: 100 Matawan Road, Suite 325 Matawan, New Jersey 07747 United States | |
Phone | 848 201 5010 |
Website | apimedsus.com |
Stock Details
Ticker Symbol | APUS |
Exchange | NYSEAMERICAN |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $4.00 |
CIK Code | 0001894525 |
CUSIP Number | 03771D102 |
ISIN Number | US03771D1028 |
Employer ID | 85-1099700 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Erik C. Emerson | Chief Executive Officer and Director |
Dr. Christopher M. H. Kim M.D. | Chief Medical Officer and Chairman |
Erick J. Frim | Chief Financial Officer |
Brian Peters | Head of Proprietary AI Division |
Dr. Susan M. Kramer Dr. P.H. | Senior Vice President of Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 19, 2025 | 10-Q | Quarterly Report |
Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Jul 16, 2025 | 8-K | Current Report |
Jun 5, 2025 | 8-K | Current Report |
May 23, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
May 20, 2025 | 8-K | Current Report |
May 20, 2025 | 10-Q | Quarterly Report |
May 19, 2025 | SCHEDULE 13D | Filing |
May 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
May 12, 2025 | 8-K | Current Report |